Integrating Patient-derived Organoid and Patient-derived Xenograft Models to Guide Precision Chemotherapy for Gastric Cancer.

BACKGROUND/AIM: The present study aimed to establish patient-derived organoid (PDO) and patient-derived xenograft (PDX) models from clinical gastric cancer (GC) tissue samples and analyze their drug sensitivity data to evaluate their translational value in GC research. The present study investigated the integrated construction of PDOs and PDXs from the same patient and evaluated their utility in individualized drug sensitivity prediction and clinical translation.

MATERIALS AND

METHODS

By constructing GC PDOs and PDXs, drug sensitivity assays with multiple agents were performed and validated results against clinical therapeutic responses. Endoscopic and surgical GC specimens were synchronously processed to generate paired PDO and PDX models from identical patient tissues. Model fidelity was validated using hematoxylin and zeosin (H&E) staining, immunohistochemistry (IHC) and short tandem repeat (STR) profiling. In vitro drug sensitivity testing and in vivo PDX pharmacodynamic validation were performed and predicted outcomes were compared to clinical treatment responses.

RESULTS

The findings demonstrated that PDOs and PDXs effectively preserve key histopathological and genetic features of the original tumors, with high concordance between drug sensitivity profiles and actual clinical outcomes, providing a platform for precision therapy in GC. Both PDOs and PDXs recapitulated the histological features of primary tumors. IHC confirmed their consistency with the original tissue profiles, while STR analysis demonstrated >90% genetic matching between the models and the source tissues. The integrated PDO-PDX platform showed a high correlation in predicting drug sensitivity.

CONCLUSION

The integrated PDO-PDX platform achieved clinical concordance in predicting drug sensitivity, providing a platform for precision therapy in GC.